Compare Li Auto Inc (LI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Li Auto Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Li Auto Inc trades at $12.24 (market cap $12.43B), while State Street SPDR S&P Biotech ETF trades at $154.18. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals.
| LI | XBI | |
|---|---|---|
Market Cap | $12.43B | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $30.84 | $164.28 |
52-Week Low | $11.74 | $85.16 |
Enterprise Value | $1.34B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LI Auto trades at $12.42, up 0.24% on the day, with a bearish technical signal and mixed earnings history. The company reported a net income margin of -1.66% for 2025, with revenue declining to $112.31B from $144.5B in 2024. Recent news highlights the launch of new SUV models like the Li L6, aiming to boost deliveries amid competitive pressures.
Outlook remains cautious with analyst consensus at Buy (43.75%) but near-term risks from intense EV competition and profitability challenges. The stock trades below the consensus price target of $14.80, offering potential upside if execution improves, but investors face headwinds from margin pressure and volatile cash flows.
XBI, the SPDR S&P Biotech ETF, trades at $150.94, down 2.14% today amid a bearish technical signal. The ETF holds 155 biotech stocks equally weighted, offering high beta exposure. Recent news highlights a 17% monthly surge driven by AI drug discovery and M&A activity, though analyst consensus remains a lone Hold rating. Key support sits at $151 with resistance at $155.
Outlook hinges on biotech sector momentum from innovation and deal flow, but risks include volatility from small-cap holdings and regulatory uncertainty. The neutral sentiment and lack of fundamental ratios suggest investors await clearer earnings trends from underlying holdings for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
